United Laboratories International Holdings First Half 2025 Earnings: Misses Expectations

Simply Wall St · 09/02/2025 06:11

United Laboratories International Holdings (HKG:3933) First Half 2025 Results

Key Financial Results

  • Revenue: CN¥7.52b (up 4.8% from 1H 2024).
  • Net income: CN¥1.89b (up 27% from 1H 2024).
  • Profit margin: 25% (up from 21% in 1H 2024). The increase in margin was primarily driven by higher revenue.
  • EPS: CN¥1.04 (up from CN¥0.82 in 1H 2024).
earnings-and-revenue-growth
SEHK:3933 Earnings and Revenue Growth September 2nd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

United Laboratories International Holdings Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 5.1%. Earnings per share (EPS) also missed analyst estimates by 22%.

Looking ahead, revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 3 warning signs for United Laboratories International Holdings (1 is concerning) you should be aware of.